Author

Stefanie Howaldt

FIRST CLINICAL EXPERIENCE OF ORAL FERRIC MALTOL TREATMENT IN PREGNANT WOMEN WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA
FIRST CLINICAL EXPERIENCE OF ORAL FERRIC MALTOL TREATMENT IN PREGNANT WOMEN WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANAEMIA

Stefanie Howaldt  et al.

COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL AND THE REDUCED USE OF INTRAVENOUS IRON BASED ON REAL WORLD DATA
COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL AND THE REDUCED USE OF INTRAVENOUS IRON BASED ON REAL WORLD DATA

Stefanie Howaldt  et al.

COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL AND THE REDUCED USE OF INTRAVENOUS IRON BASED ON REAL WORLD DATA
COSTS SAVINGS ASSOCIATED WITH FERRIC MALTOL AND THE REDUCED USE OF INTRAVENOUS IRON BASED ON REAL WORLD DATA

COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRIC MALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH MILD-TO-MODERATE VS. MORE SEVERE IRON DEFICIENCY ANAEMIA
COMPARATIVE EFFICACY AND SAFETY OF ORAL FERRIC MALTOL IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH MILD-TO-MODERATE VS. MORE SEVERE IRON DEFICIENCY ANAEMIA

Stefanie Howaldt  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY

Stefanie Howaldt  et al.

Item 1 - 5 / 5
1